Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
glecaprevir/pibrentasvir (GLE/PIB)
DRUG
2 trials
Sponsors
University of California, San Diego
, AbbVie
Conditions
Hepatitis C
Hepatitis C Virus (HCV)
Hepatitis C Virus Infection, Response to Therapy of
Phase 1
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
Completed
NCT04596475
University of California, San Diego
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Start: 2021-05-28
End: 2022-04-21
Updated: 2022-05-24
Phase 3
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Completed
NCT04903626
AbbVie
Hepatitis C Virus (HCV)
Start: 2021-08-24
End: 2024-09-17
Updated: 2025-04-06
Related Papers
Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection.
2026-06-24
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
2025-11-24
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.
2023-07-27
6 citations